ArticleJournal of Cancer2026
A digital polymerase chain reaction method targeting non-recombined T-cell receptor sequences aids in diagnosing primary cutaneous T-cell lymphomas.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diagnosing primary cutaneous T-cell lymphoma (PCTCL) relies on the comprehensive evaluation of clinical presentation, histopathology, immune profile, and molecular testing. Regarding molecular testing, the BIOMED-2 assay is most commonly used for detecting monoclonality of T-cell receptor (TCR) genes. However, its sensitivity is not ideal for PCTCLs, and a supplementary test is required. We recently found that the ratios of non-recombined TCR sequences J2-2P and J2-3 of the Methods: Formalin-fixed paraffin-embedded tissue samples of clinicopathologically proven PCTCL cases with a negative BIOMED-2 clonality result were retrospectively retrieved, and the clinicopathological characteristics were collected. After RNA extraction and quality checking, dPCR was performed on PCTCL specimens and control samples to quantify the J2-2P and J2-3 sequences. Results: We collected 35 skin biopsy samples from patients with early-stage PCTCL and 11 inflammatory dermatoses as controls. Ratios of the J2-2P to J2-3 concentration in controls ranged from 0.03 to 0.55% (mean ± standard deviation: 0.21 ± 0.17%). In contrast, 25 of the 35 (71.42%) PCTCL specimens exhibited J2-2P/J2-3 ratios exceeding the defined upper limit of the control group. Conclusion: Our dPCR assay on the non-recombined
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.